News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Corixa Corporation (CRXA) Announces Fourth Quarter And Year-End 2004 Financial Results


10/19/2005 5:13:00 PM

SEATTLE--(BUSINESS WIRE)--March 14, 2005--Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced financial results for the fourth quarter and year ended December 31, 2004. For the fourth quarter of 2004, Corixa reported total revenue of $8.3 million compared with total revenue of $12.5 million for the fourth quarter of 2003. Net loss applicable to common stockholders for the fourth quarter of 2004 was $24.8 million, compared with net loss of $16.9 million for the fourth quarter of 2003. Diluted net loss per common share for the fourth quarter of 2004 was $0.42 compared with diluted net loss per common share of $0.31 for the fourth quarter of 2003. Excluding acquisition-related charges, such as intangible and deferred compensation amortization, a lease-related impairment charge and restructuring charges, net loss applicable to common stockholders and diluted net loss per common share for the fourth quarter of 2004 were $20.1 million and $0.34, respectively, compared with net loss applicable to common stockholders and diluted net loss per common share of $14.4 million and $0.26, respectively for the fourth quarter of 2003.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES